Reduced glucose uptake and Aβ in brain regions with hyperintensities in connected white matter

NeuroImage

Volumn 100, Issue , 2014, Pages 684-691

  Glodzik, L ^a   Kuceyeski, A ^b   Rusinek, H ^a   Tsui, W ^a   Mosconi, L ^a   Li, Y ^a   Osorio, R S ^a   Williams, S ^a   Randall, C ^a   Spector, N ^a   McHugh, P ^a   Murray, J ^a   Pirraglia, E ^a   Vallabhajosula, S ^b   Raj, A ^b   de Leon, M J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEIL FAMILY BRAIN AND MIND RESEARCH INSTITUTE   (United States)

Author keywords

Aging; Amyloid beta; Cerebrovascular disorders; Magnetic resonance imaging; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE; GLUCOSE; PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GLUCOSE BLOOD LEVEL; THIAZOLE DERIVATIVE;

ADULT; ANTERIOR CINGULATE; ARTICLE; BRAIN REGION; CALCARINE SULCUS; CAUDATE NUCLEUS; CEREBELLUM CORTEX; CHANGE IN CONNECTIVITY SCORE; CONNECTOME; CONTROLLED STUDY; FEMALE; FRONTAL LOBE; GLUCOSE TRANSPORT; GRAY MATTER; HUMAN; HUMAN EXPERIMENT; INSULA; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; SCORING SYSTEM; SUBCORTEX; TEMPORAL LOBE; THALAMUS; WHITE MATTER; WHITE MATTER LESION; AGED; BRAIN; DIAGNOSTIC USE; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BLOOD GLUCOSE; BRAIN; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; THIAZOLES; WHITE MATTER;

EID: 84908355918     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2014.06.060     Document Type: Article

References (46)

1. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. Neuroimage 2000, 11:805-821.
2. Bech P., Kastrup M., Rafaelsen O.J. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr. Scand. Suppl. 1986, 326:1-37.
3. Bero A.W., Yan P., Roh J.H., Cirrito J.R., Stewart F.R., Raichle M.E., Lee J.-M., Holtzman D.M. Neuronal activity regulates the regional vulnerability to amyloid-β deposition. Nat. Neurosci. 2011, 14:750-756.
4. Buckner R.L., Sepulcre J., Talukdar T., Krienen F.M., Liu H., Hedden T., Andrews-Hanna J.R., Sperling R.A., Johnson K.A. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J. Neurosci. 2009, 29:1860-1873.
5. Carter S.F., Schöll M., Almkvist O., Wall A., Engler H., Långström B., Nordberg A. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-l-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 2012, 53:37-46.
6. Cirrito J.R., Yamada K.A., Finn M.B., Sloviter R.S., Bales K.R., May P.C., Schoepp D.D., Paul S.M., Mennerick S., Holtzman D.M. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48:913-922.
7. Cohen A.D., Price J.C., Weissfeld L.A., James J., Rosario B.L., Bi W., Nebes R.D., Saxton J.A., Snitz B.E., Aizenstein H.A., Wolk D.A., Dekosky S.T., Mathis C.A., Klunk W.E. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J. Neurosci. 2009, 29:14770-14778.
8. De Leeuw F.E., de Groot J.C., Achten E., Oudkerk M., Ramos L.M., Heijboer R., Hofman A., Jolles J., van Gijn J., Breteler M.M. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J. Neurol. Neurosurg. Psychiatry 2001, 70:9-14.
9. DeCarli C., Murphy D.G., Tranh M., Grady C.L., Haxby J.V., Gillette J.A., Salerno J.A., Gonzales-Aviles A., Horwitz B., Rapoport S.I. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology 1995, 45:2077-2084.
10. Draper N.R., Smith H. Applied Regression Analysis (Wiley Series in Probability and Statistics) 1998, Wiley-Interscience.
11. Drzezga A., Grimmer T., Henriksen G., Stangier I., Perneczky R., Diehl-Schmid J., Mathis C.A., Klunk W.E., Price J., DeKosky S., Wester H.-J., Schwaiger M., Kurz A. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage 2008, 39:619-633.
12. Edison P., Archer H.A., Hinz R., Hammers A., Pavese N., Tai Y.F., Hotton G., Cutler D., Fox N., Kennedy A., Rossor M., Brooks D.J. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology 2007, 68:501-508.
13. Filley C.M. White matter: organization and functional relevance. Neuropsychol. Rev. 2010, 20:158-173.
14. Folstein M.F. The mini-mental state examination. Arch. Gen. Psychiatry 1983, 40:812.
15. Förster S., Grimmer T., Miederer I., Henriksen G., Yousefi B.H., Graner P., Wester H.-J., Förstl H., Kurz A., Dickerson B.C., Bartenstein P., Drzezga A. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol. Psychiatry 2012, 71:792-797.
16. Frost B., Ollesch J., Wille H., Diamond M.I. Conformational diversity of wild-type Tau fibrils specified by templated conformation change. J. Biol. Chem. 2009, 284:3546-3551.
17. Furst A.J., Rabinovici G.D., Rostomian A.H., Steed T., Alkalay A., Racine C., Miller B.L., Jagust W.J. Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol. Aging 2012, 33:215-225.
18. Grimmer T., Faust M., Auer F., Alexopoulos P., Förstl H., Henriksen G., Perneczky R., Sorg C., Yousefi B.H., Drzezga A., Kurz A. White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol. Aging 2012, 33:2766-2773.
19. Hedden T., Mormino E.C., Amariglio R.E., Younger A.P., Schultz A.P., Becker J.A., Buckner R.L., Johnson K.A., Sperling R.A., Rentz D.M. Cognitive profile of amyloid burden and white matter hyperintensities in cognitively normal older adults. J. Neurosci. 2012, 32:16233-16242.
20. Honey C.J., Sporns O., Cammoun L., Gigandet X., Thiran J.P., Meuli R., Hagmann P. Predicting human resting-state functional connectivity from structural connectivity. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2035-2040.
21. Jagust W.J., Mormino E.C. Lifespan brain activity, β-amyloid, and Alzheimer's disease. Trends Cogn. Sci. 2011, 15:520-526.
22. Kang J.-E., Lim M.M., Bateman R.J., Lee J.J., Smyth L.P., Cirrito J.R., Fujiki N., Nishino S., Holtzman D.M. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 2009, 326:1005-1007.
23. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergström M., Savitcheva I., Huang G., Estrada S., Ausén B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
24. Kochunov P., Ramage A.E., Lancaster J.L., Robin D.A., Narayana S., Coyle T., Royall D.R., Fox P. Loss of cerebral white matter structural integrity tracks the gray matter metabolic decline in normal aging. Neuroimage 2009, 45:17-28.
25. Kuceyeski A., Maruta J., Relkin N., Raj A. The Network Modification (NeMo) Tool: elucidating the effect of white matter integrity changes on cortical and subcortical structural connectivity. Brain Connect. 2013, 3.
26. Kuczynski B., Reed B., Mungas D., Weiner M., Chui H.C., Jagust W. Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease. Arch. Neurol. 2008, 65:650-655.
27. Li Y., Rinne J.O., Mosconi L., Pirraglia E., Rusinek H., DeSanti S., Kemppainen N., Någren K., Kim B.-C., Tsui W., de Leon M.J. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2169-2181.
28. Lowe V.J., Weigand S.D., Senjem M.L., Vemuri P., Jordan L., Kantarci K., Boeve B., Jack C.R., Knopman D., Petersen R.C. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 2014, (Epub ahead of print). 10.1212/WNL.0000000000000467.
29. Marchant N.L., Reed B.R., DeCarli C.S., Madison C.M., Weiner M.W., Chui H.C., Jagust W.J. Cerebrovascular disease, β-amyloid, and cognition in aging. Neurobiol. Aging 2012, 33:1006. (e25-36).
30. Mikheev A., Nevsky G., Govindan S., Grossman R., Rusinek H. Fully automatic segmentation of the brain from T1-weighted MRI using Bridge Burner algorithm. J. Magn. Reson. Imaging 2008, 27:1235-1241.
31. Nordahl C.W., Ranganath C., Yonelinas A.P., Decarli C., Fletcher E., Jagust W.J. White matter changes compromise prefrontal cortex function in healthy elderly individuals. J. Cogn. Neurosci. 2006, 18:418-429.
32. Oh H., Habeck C., Madison C., Jagust W. Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum. Brain Mapp. 2014, 35:297-308.
33. Palop J.J., Mucke L. Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat. Neurosci. 2010, 13:812-818.
34. Provenzano F.A., Muraskin J., Tosto G., Narkhede A., Wasserman B.T., Griffith E.Y., Guzman V.A., Meier I.B., Zimmerman M.E., Brickman A.M. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?. JAMA Neurol. 2013, 70:455-461.
35. Raj A., Kuceyeski A., Weiner M. A network diffusion model of disease progression in dementia. Neuron 2012, 73:1204-1215.
36. Reed B.R., Eberling J.L., Mungas D., Weiner M., Kramer J.H., Jagust W.J. Effects of white matter lesions and lacunes on cortical function. Arch. Neurol. 2004, 61:1545-1550.
37. Reisberg B., Sclan S., Franssen E., Deleon M., Kluger A., Torossian C., Shulman E., Steinberg G., Monteiro I., Mcrae T., Boksay I., Mackell J., Ferris S. Clinical stages of normal aging and Alzheimer's disease: the GDS staging system. Neurosci. Res. Commun. 1993, 13:S51-S54.
38. Rosenbloom M.H., Alkalay A., Agarwal N., Baker S.L., O'Neil J.P., Janabi M., Yen I.V., Growdon M., Jang J., Madison C., Mormino E.C., Rosen H.J., Gorno-Tempini M.L., Weiner M.W., Miller B.L., Jagust W.J., Rabinovici G.D. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011, 76:1789-1796.
39. Scarpelli M., Salvolini U., Diamanti L., Montironi R., Chiaromoni L., Maricotti M. MRI and pathological examination of post-mortem brains: the problem of white matter high signal areas. Neuroradiology 1994, 36:393-398.
40. Scheltens P., Barkhof F., Leys D., Wolters E.C., Ravid R., Kamphorst W. Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. Neurology 1995, 45:883-888.
41. Sled J.G., Zijdenbos A.P., Evans A.C. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans. Med. Imaging 1998, 17:87-97.
42. Sultzer D.L., Chen S.T., Brown C.V., Mahler M.E., Cummings J.L., Hinkin C.H., Mandelkern M.A. Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings. J. Neuropsychiatry Clin. Neurosci. 2002, 14:262-269.
43. Tullberg M., Fletcher E., DeCarli C., Mungas D., Reed B.R., Harvey D.J., Weiner M.W., Chui H.C., Jagust W.J. White matter lesions impair frontal lobe function regardless of their location. Neurology 2004, 63:246-253.
44. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002, 15:273-289.
45. Yokokura M., Mori N., Yagi S., Yoshikawa E., Kikuchi M., Yoshihara Y., Wakuda T., Sugihara G., Takebayashi K., Suda S., Iwata Y., Ueki T., Tsuchiya K.J., Suzuki K., Nakamura K., Ouchi Y. In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2011, 38:343-351.
46. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.